Skip to main navigation Skip to search Skip to main content

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)

  • Fleming, Shaun (Primary Chief Investigator (PCI))
  • Grove, Carolyn S. (Partner Investigator (PI))
  • Menzies, Anna (Partner Investigator (PI))
  • Armytage, Tasman (Partner Investigator (PI))
  • Chuah, Hun-Sheng (Partner Investigator (PI))
  • Choong, Hock Lai (Partner Investigator (PI))
  • Grabek, Julian (Partner Investigator (PI))
  • Pnoraj, Royston (Chief Investigator (CI))
  • Agrawal, Shivam (Chief Investigator (CI))
  • Yannakou, Costas Kleanthes (Chief Investigator (CI))
  • Shuttleworth, Charles (Chief Investigator (CI))
  • Baker, Ross (Chief Investigator (CI))

Project: Research

Project Details

Short titleREVEAL-ND NPM1
StatusActive
Effective start/end date30/04/26 → 29/04/28

Keywords

  • clinical trials
  • phase 3
  • acute myeloid leukaemia (AML)
  • NPM1 mutation
  • REVEAL-ND NPM1
  • SNDX-5613-0710

Clinical Trial Phase

  • Phase III (a & b)